Protecting patient access to discounted medications and health care services through Washington's health care safety net by preventing manufacturer limitations on the 340B drug pricing program.

Penalties now apply to third parties acting on behalf of manufacturers, not just manufacturers, distributors, or third-party logistics providers.

Reporting deadlines changed from a fixed April 1st date to 'on or before April 1st following the conclusion of the fiscal year,' and reporting now covers the previous fiscal year instead of calendar year.

New reporting categories require covered entities to disclose savings usage details, total savings on administered outpatient drugs, and specific claim counts for dispensed versus administered drugs.

Manufacturer reporting now includes the average discount on the top 25 drugs and details on inflationary rebates and caps.

Public reports will aggregate data differently, allowing specific identification for certain covered entity data while keeping manufacturer data aggregated to protect privacy.

Covered entities must be given a 30-day grace period to correct reporting violations before fines are issued.

Filing fees for covered entities must now be tiered based on their gross operating revenue.

The definition of 'Package' was removed from the bill text, and references to 'distributor' and 'third-party logistics provider' were removed from the prohibited acts section.

The bill title and sponsor list were updated to reflect that the bill is now a 'Substitute Bill' and to include the Senate Health & Long-Term Care committee as the current sponsor.

The legislative summary was updated to explicitly state that the bill amends RCW 43.71C.100, clarifying its interaction with existing data reporting laws.

The final section was renumbered and adjusted to reflect that Sections 1 through 5 now constitute the new chapter, replacing the previous reference to Sections 1 through 4.

A new requirement was added (Sec. 5) mandating that covered entities submit detailed annual reports on 340B drug usage, costs, and savings to the state department by April 1st.

A new penalty provision was added, allowing the department to fine covered entities up to $1,000 per day for failing to submit the required reports.

The bill's title and legislative findings were updated to explicitly include protecting the integrity of the 340B program, not just patient access.

New reporting requirements were added for covered entities, requiring them to report specific data on 340B drug usage, savings utilization, and payments to contract pharmacies.

New reporting requirements were added for manufacturers, requiring them to submit data on drug production costs, marketing expenses, and specific 340B distribution details.

Definitions for 'covered drug' were updated to include specific thresholds for high-cost drugs and price increase triggers.

A new filing fee mechanism was added to allow the authority to charge manufacturers and covered entities to cover the costs of administering data collection.

Confidentiality rules were changed to allow specific 340B data regarding manufacturers and covered entities to be publicly released for policy analysis.

Penalties for non-compliance were adjusted and clarified, with fines now deposited into the Medicaid fraud penalty account.

The effective date for the first reading of the bill was updated from January 28 to February 9, 2026.